MX9200485A - Proceso para la obtencion de derivados de tetra hidro piridina y composicion farmaceutica que los contiene. - Google Patents

Proceso para la obtencion de derivados de tetra hidro piridina y composicion farmaceutica que los contiene.

Info

Publication number
MX9200485A
MX9200485A MX9200485A MX9200485A MX9200485A MX 9200485 A MX9200485 A MX 9200485A MX 9200485 A MX9200485 A MX 9200485A MX 9200485 A MX9200485 A MX 9200485A MX 9200485 A MX9200485 A MX 9200485A
Authority
MX
Mexico
Prior art keywords
piridina
hidro
tetra
pharmaceutical composition
compounds
Prior art date
Application number
MX9200485A
Other languages
English (en)
Inventor
Michel Heaulme
Umberto Guzzi
Original Assignee
Sanofi Elf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Elf filed Critical Sanofi Elf
Publication of MX9200485A publication Critical patent/MX9200485A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX9200485A 1991-02-05 1992-02-04 Proceso para la obtencion de derivados de tetra hidro piridina y composicion farmaceutica que los contiene. MX9200485A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9101283A FR2672213B1 (fr) 1991-02-05 1991-02-05 Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.

Publications (1)

Publication Number Publication Date
MX9200485A true MX9200485A (es) 1992-11-01

Family

ID=9409370

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9200485A MX9200485A (es) 1991-02-05 1992-02-04 Proceso para la obtencion de derivados de tetra hidro piridina y composicion farmaceutica que los contiene.

Country Status (13)

Country Link
US (1) US5292745A (es)
EP (1) EP0498718B1 (es)
JP (1) JP3471820B2 (es)
AT (1) ATE109467T1 (es)
AU (1) AU649099B2 (es)
CA (1) CA2060616C (es)
DE (1) DE69200284T2 (es)
DK (1) DK0498718T3 (es)
ES (1) ES2061319T3 (es)
FR (1) FR2672213B1 (es)
HU (2) HU212945B (es)
IE (1) IE66593B1 (es)
MX (1) MX9200485A (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
UA57004C2 (uk) * 1995-10-26 2003-06-16 Санофі - Сінтелябо Лікувальний засіб, що містить 1-(2-нафт-2-ілетил)-4-(3-трифторметилфеніл)-1,2,3,6,-тетрагідропіридин (варіанти), та спосіб лікування бічного аміотрофічного склерозу
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
FR2763847B1 (fr) 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
AU769633B2 (en) * 1998-12-01 2004-01-29 Bradley P Fuhrman Method for reducing free-radical induced injury
WO2003020281A1 (en) * 2001-08-29 2003-03-13 Alcon, Inc. Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
JP2008504279A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
AU2005258248A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
US7687665B2 (en) * 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
MX2007001540A (es) * 2004-08-10 2007-04-23 Incyte Corp Compuestos amido y sus usos como farmaceuticos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2501682A1 (fr) * 1981-03-11 1982-09-17 Sanofi Sa Trifluoromethylphenylpyridines a activite anorexigene, un procede de preparation et compositions pharmaceutiques en contenant
US4691019A (en) * 1981-03-11 1987-09-01 Sanofi Anorectic agent; 4-(3-trifluoromethylphenyl)-1-(2-cyanoethyl)-1,2,3,6-tetrahydropyridine
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
GB2226269B (en) * 1988-12-22 1992-11-25 Zdzislaw Bieganski Cable stripper
FR2650505B1 (fr) * 1989-08-07 1994-06-03 Midy Spa Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
HU212945B (en) 1996-12-30
HUT62563A (en) 1993-05-28
IE920354A1 (en) 1992-08-12
ATE109467T1 (de) 1994-08-15
AU649099B2 (en) 1994-05-12
JP3471820B2 (ja) 2003-12-02
DK0498718T3 (da) 1994-12-05
EP0498718B1 (fr) 1994-08-03
DE69200284D1 (de) 1994-09-08
JPH04312528A (ja) 1992-11-04
CA2060616C (en) 2004-04-06
HU9200335D0 (en) 1992-04-28
FR2672213A1 (fr) 1992-08-07
EP0498718A1 (fr) 1992-08-12
ES2061319T3 (es) 1994-12-01
IE66593B1 (en) 1996-01-24
DE69200284T2 (de) 1995-03-02
FR2672213B1 (fr) 1995-03-10
US5292745A (en) 1994-03-08
CA2060616A1 (en) 1992-08-06
AU1065592A (en) 1992-08-13
HU211457A9 (en) 1995-11-28

Similar Documents

Publication Publication Date Title
ATE40368T1 (de) Xanthin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
MX9200485A (es) Proceso para la obtencion de derivados de tetra hidro piridina y composicion farmaceutica que los contiene.
DK92781A (da) Fremgangsmaade til fremstilling af indanderivater eller syreadditionssalte deraf
SE8406302D0 (sv) New aminoguanidine derivatives and a process for the preparation thereof
DK163144C (da) Diethylaminoalkoxybenzhydrolderivater og farmaceutisk acceptable syreadditionssalte og kvaternaere ammoniumsalte deraf, fremgangsmaade til fremstilling heraf, farmaceutisk praeparat og fremgangsmaade til fremstilling heraf
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
FI834800A (fi) Foerfarande foer framstaellning av dialkylaminoalkoxibensylalkohol-derivat.
ATE62908T1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
ATE23995T1 (de) Pyridin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE28632T1 (de) Piperidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE23150T1 (de) Aminoethoxybenzylalkohol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE28647T1 (de) Chinazolinonderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
ATE26271T1 (de) Benzhydrylpiperazine-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE4541T1 (de) Alkyl- und cycloalkylsubstituierte 2-(2-(2hydroxy-3-tert.-butylamino-propoxy)-5-acylamino phenyl)-1,3,4-oxadiazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen.
TH20908B (th) อนุพันธ์คาร์โบไฮเดรต
TH31635A (th) อนุพันธ์คาร์โบไฮเดรต

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: NOVOZYMES A/S

MM Annulment or lapse due to non-payment of fees